Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
Merck discontinues Victrelis (boceprevir) voluntarily in the United States

Merck has decided to voluntarily discontinue the manufacture and distribution of Victrelis in the United States by December 2015.

Published
21 January 2015
From
EATG
Gilead and AbbVie take hepatitis C battle to Europe

Europe is to become the next battleground between Gilead Sciences and AbbVie in their scramble to win share of the fast-growing market for hepatitis C drugs. The companies have been fighting a high-profile price war in the US over a new generation of blockbuster medicines that can cure most people with the virus within weeks. The pair are preparing to open a new front across the Atlantic after European regulators gave AbbVie’s hepatitis C treatment the green light on Friday.

Published
20 January 2015
From
Financial Times (free registration required)
The Cynical Connectedness of Gilead's Hepatitis C Pricing and Anti-Diversion Policies

Gilead has announced both the highest recorded prices ever for its direct acting hepatitis C antiviral, ledipasvir/sofosbuvir (Harvoni), and one of the most stringent anti-diversion programs ever devised. The price, highest in the U.S., comes in at a whopping US$94,000 for a 12-week course of treatment, with slightly lower prices in Europe.

Published
19 January 2015
From
The Body Pro
Hepatitis C drug delayed by NHS due to high cost

The NHS is to delay the introduction of a highly expensive drug that can save the lives of people infected with the hepatitis C virus. The move by NHS England is unprecedented, because the NHS rationing body, Nice (the National Institute for Health and Care Excellence) has approved the drug. Nice says sofosbuvir is cost-effective, because it is a cure for people who would otherwise run up huge NHS bills.

Published
16 January 2015
From
The Guardian
European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for the Treatment of Chronic Hepatitis C

The treatment has been approved with or without ribavirin (RBV) for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients.1,2 Additionally, VIEKIRAX has been approved for use with RBV in genotype 4 (GT4) chronic hepatitis C patients.

Published
16 January 2015
From
AbbVie press release
How Much Could AbbVie Inc. Make Selling Its Hepatitis C Drug This Year?

AbbVie has issued its guidance for 2015, and that guidance suggests that its newly launched hepatitis C drug cocktail, Viekira Pak, could be a big driver of earnings growth this year. In December, Viekira Pak received FDA approval as a treatment for hepatitis C genotype 1 after delivering compelling functional cure rates in the mid-90% range during clinical trials. That approval was highly anticipated by health care payers desperate for competition in this market, because hepatitis C market share leader Gilead Sciences' two hepatitis C drugs, Sovaldi and Harvoni, carry eye-popping price tags that are translating into billions of additional dollars in health care spending.

Published
15 January 2015
From
The Motley Fool
India rejects Gilead's Hepatitis C drug patent request

India's patent office has rejected an application from U.S.-based Gilead Sciences Inc for its hepatitis C drug Sovaldi, paving the way for local drugmakers to launch cheaper generic versions of the $1,000-a-pill medicine.

Published
14 January 2015
From
Reuters
Doctors Question Wider Hepatitis C Screening Despite Cures

Doctors should resist the urge to screen a wider group of patients for hepatitis C, a group of physicians said today in the British Medical Journal, despite the introduction of new drugs that can cure the liver disease. Expanded screening would flag the disease in people who are unlikely to die from it, leading to unnecessary treatment that may itself be harmful, said the group, including Kenneth Lin, an associate professor at Georgetown University School of Medicine.

Published
14 January 2015
From
Bloomberg
US: Prime Therapeutics breaks from competition, strikes deals to prefer both Harvoni, Viekira hepatitis C drugs

The agreements place both Gilead’s Harvoni® and AbbVie’s Viekira Pak® on Prime’s preferred drug list (formulary), meaning members can more easily get the medicine they need to feel better and live well.

Published
13 January 2015
From
Prime Therapeutics press release
Spaniards rally over hepatitis C drugs

Thousands of people, diagnosed with hepatitis C, have rallied in several cities across Spain to urge the government to make it easier for patients with this disease to access the latest-generation medicines.

Published
12 January 2015
From
Press TV
← First12345...50Next →

Filter by country